Press Releases

AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 27, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will present new preclinical data on novel assays used to evaluate lentiviral vector

Sep 27, 2022

AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis

Second AVROBIO gene therapy program that has been granted rare pediatric disease designation by FDA AVR-RD-04 has previously received orphan drug designation from FDA and EMA CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 20, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy

Sep 20, 2022

AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

First in-human pediatric Phase 1/2 study to evaluate the safety and tolerability of first-in-class gene therapy targeting infants age ≥3 months and ≤12 months, diagnosed with nMPS-II University of Manchester ( U.K. ) expects to initiate clinical trial later this year U.S.

Sep 14, 2022

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 8, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 58,000 restricted stock units (RSUs) to three new

Sep 08, 2022

AVROBIO to Participate in Four Upcoming Investor Conferences in September

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 31, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming

Aug 31, 2022

AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update

Presented positive data from first five patients in Phase 1/2 cystinosis trial 1   showing systemic gene therapy effect at the American Society of Gene and Cell Therapy Annual Meeting; all five patients remain off oral cysteamine Comprehensive Gaucher disease franchise update planned for Q4 2022

Aug 09, 2022

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 4, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 35,500 restricted stock units (RSUs)

Aug 04, 2022

AVROBIO to Participate in Two Upcoming Investor Conferences in August

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two

Aug 01, 2022

AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

AVR-RD-05 is the fourth AVROBIO gene therapy to receive orphan drug designation FDA previously granted rare pediatric disease designation for AVR-RD-05 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 13, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared

Jul 13, 2022

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 6, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 37,500 restricted stock units (RSUs)

Jul 06, 2022



Displaying 1 - 10 of 27

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.